• When to keep it simple - adaptive designs are not always useful. 

  Wason, JMS; Brocklehurst, P; Yap, C (2019-08-02)

  BACKGROUND: Adaptive designs are a wide class of methods focused on improving the power, efficiency and participant benefit of clinical trials. They do this through allowing information gathered during the trial to be used ...
• An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. 

  O'Reilly, A; Hughes, P; Mann, J; Lai, Z; Teh, JJ; Mclean, E; Edmonds, K; Lingard, K; Chauhan, D; Lynch, J; Au, L; Ludlow, A; Pattison, N; Wiseman, T; Turajlic, S; Gore, M; Larkin, J; Husson, O (2019-05-14)

  PURPOSE: The immune checkpoint inhibitors (ICIs) have resulted in subgroups of patients with metastatic melanoma achieving high-quality durable responses. Metastatic melanoma survivors are a new population in the era of ...
• Alternative splicing in prostate cancer. 

  Paschalis, A; Sharp, A; Welti, JC; Neeb, A; Raj, GV; Luo, J; Plymate, SR; de Bono, JS (2018-11)

  Androgen receptor (AR) splice variants (AR-Vs) have been implicated in the development and progression of metastatic prostate cancer. AR-Vs are truncated isoforms of the AR, a subset of which lack a ligand-binding domain ...
• Quality assuring “Plan of the day” selection in a multicentre adaptive bladder trial: Implementation of a pre-accrual IGRT guidance and assessment module 

  Patel, E; Tsang, Y; Baker, A; Callender, J; Hafeez, S; Hall, E; Hansen, VN; Lewis, R; McNair, H; Miles, E; Huddart, R (Elsevier BV, 2019-11)
• Spatially constrained tumour growth affects the patterns of clonal selection and neutral drift in cancer genomic data. 

  Chkhaidze, K; Heide, T; Werner, B; Williams, MJ; Huang, W; Caravagna, G; Graham, TA; Sottoriva, A (2019-07)

  Quantification of the effect of spatial tumour sampling on the patterns of mutations detected in next-generation sequencing data is largely lacking. Here we use a spatial stochastic cellular automaton model of tumour growth ...
• Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. 

  Perez-Lopez, R; Tunariu, N; Padhani, AR; Oyen, WJG; Fanti, S; Vargas, HA; Omlin, A; Morris, MJ; de Bono, J; Koh, D-M (2019-08)

  The management of advanced prostate cancer has changed substantially with the availability of multiple effective novel treatments, which has led to improved disease survival. In the era of personalized cancer treatments, ...
• Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers. 

  Cortes, J; Tamura, K; DeAngelo, DJ; de Bono, J; Lorente, D; Minden, M; Uy, GL; Kantarjian, H; Chen, LS; Gandhi, V; Godin, R; Keating, K; McEachern, K; Vishwanathan, K; Pease, JE; Dean, E (2018-05)

  BACKGROUND: Proviral integration Moloney virus (PIM) kinases (PIM1, 2 and 3) are overexpressed in several tumour types and contribute to oncogenesis. AZD1208 is a potent ATP-competitive PIM kinase inhibitor investigated ...
• Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer. 

  Sharp, A; Welti, JC; Lambros, MBK; Dolling, D; Rodrigues, DN; Pope, L; Aversa, C; Figueiredo, I; Fraser, J; Ahmad, Z; Lu, C; Rescigno, P; Kolinsky, M; Bertan, C; Seed, G; Riisnaes, R; Miranda, S; Crespo, M; Pereira, R; Ferreira, A; Fowler, G; Ebbs, B; Flohr, P; Neeb, A; Bianchini, D; Petremolo, A; Sumanasuriya, S; Paschalis, A; Mateo, J; Tunariu, N; Yuan, W; Carreira, S; Plymate, SR; Luo, J; de Bono, JS (2019-04-27)

  BACKGROUND: Detection of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumour cells (CTCs) is associated with worse outcome in metastatic castration-resistant prostate cancer (mCRPC). However, studies ...
• Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial. 

  Judson, I; Morden, JP; Kilburn, L; Leahy, M; Benson, C; Bhadri, V; Campbell-Hewson, Q; Cubedo, R; Dangoor, A; Fox, L; Hennig, I; Jarman, K; Joubert, W; Kernaghan, S; López Pousa, A; McNeil, C; Seddon, B; Snowdon, C; Tattersall, M; Toms, C; Martinez Trufero, J; Bliss, JM (2019-07)

  BACKGROUND: Alveolar soft-part sarcoma (ASPS) is a rare soft-tissue sarcoma that is unresponsive to chemotherapy. Cediranib, a tyrosine-kinase inhibitor, has shown substantial activity in ASPS in non-randomised studies. ...
• Genomic correlates of clinical outcome in advanced prostate cancer. 

  Abida, W; Cyrta, J; Heller, G; Prandi, D; Armenia, J; Coleman, I; Cieslik, M; Benelli, M; Robinson, D; Van Allen, EM; Sboner, A; Fedrizzi, T; Mosquera, JM; Robinson, BD; De Sarkar, N; Kunju, LP; Tomlins, S; Wu, YM; Nava Rodrigues, D; Loda, M; Gopalan, A; Reuter, VE; Pritchard, CC; Mateo, J; Bianchini, D; Miranda, S; Carreira, S; Rescigno, P; Filipenko, J; Vinson, J; Montgomery, RB; Beltran, H; Heath, EI; Scher, HI; Kantoff, PW; Taplin, M-E; Schultz, N; deBono, JS; Demichelis, F; Nelson, PS; Rubin, MA; Chinnaiyan, AM; Sawyers, CL (2019-06-04)

  Heterogeneity in the genomic landscape of metastatic prostate cancer has become apparent through several comprehensive profiling efforts, but little is known about the impact of this heterogeneity on clinical outcome. Here, ...
• Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers. 

  Stewart, A; Coker, EA; Pölsterl, S; Georgiou, A; Minchom, AR; Carreira, S; Cunningham, D; O'Brien, ME; Raynaud, FI; de Bono, JS; Al-Lazikani, B; Banerji, U (2019-08)

  It is increasingly appreciated that drug response to different cancers driven by the same oncogene is different and may relate to differences in rewiring of signal transduction. We aimed to study differences in dynamic ...
• Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. 

  Banerji, U; van Herpen, CML; Saura, C; Thistlethwaite, F; Lord, S; Moreno, V; Macpherson, IR; Boni, V; Rolfo, C; de Vries, EGE; Rottey, S; Geenen, J; Eskens, F; Gil-Martin, M; Mommers, EC; Koper, NP; Aftimos, P (2019-08)

  BACKGROUND: Trastuzumab duocarmazine is a novel HER2-targeting antibody-drug conjugate comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical studies showed promising antitumour ...
• Differential impact of RB status on E2F1 reprogramming in human cancer. 

  McNair, C; Xu, K; Mandigo, AC; Benelli, M; Leiby, B; Rodrigues, D; Lindberg, J; Gronberg, H; Crespo, M; De Laere, B; Dirix, L; Visakorpi, T; Li, F; Feng, FY; de Bono, J; Demichelis, F; Rubin, MA; Brown, M; Knudsen, KE (2018-01-02)

  The tumor suppressor protein retinoblastoma (RB) is mechanistically linked to suppression of transcription factor E2F1-mediated cell cycle regulation. For multiple tumor types, loss of RB function is associated with poor ...
• Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. 

  de Bono, JS; Chowdhury, S; Feyerabend, S; Elliott, T; Grande, E; Melhem-Bertrandt, A; Baron, B; Hirmand, M; Werbrouck, P; Fizazi, K (2018-07)

  BACKGROUND: Enzalutamide and abiraterone acetate plus prednisone, which target the androgen receptor axis, have expanded the treatment of advanced prostate cancer. Retrospective analyses suggest some cross-resistance between ...
• SOX9 is a driver of aggressive prostate cancer by promoting invasion, cell fate and cytoskeleton alterations and epithelial to mesenchymal transition. 

  Francis, JC; Capper, A; Ning, J; Knight, E; de Bono, J; Swain, A (2018-01-26)

  Aggressive lethal prostate cancer is characterised by tumour invasion, metastasis and androgen resistance. Understanding the mechanisms by which localised disease progresses to advanced lethal stages is key to the development ...
• BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer. 

  Li, X; Baek, G; Ramanand, SG; Sharp, A; Gao, Y; Yuan, W; Welti, J; Rodrigues, DN; Dolling, D; Figueiredo, I; Sumanasuriya, S; Crespo, M; Aslam, A; Li, R; Yin, Y; Mukherjee, B; Kanchwala, M; Hughes, AM; Halsey, WS; Chiang, C-M; Xing, C; Raj, GV; Burma, S; de Bono, J; Mani, RS (2018-01-16)

  BRD4 belongs to the bromodomain and extraterminal (BET) family of chromatin reader proteins that bind acetylated histones and regulate gene expression. Pharmacological inhibition of BRD4 by BET inhibitors (BETi) has indicated ...
• Ataxia Telangiectasia Mutated Protein Loss and Benefit From Oxaliplatin-based Chemotherapy in Colorectal Cancer. 

  Sundar, R; Miranda, S; Rodrigues, DN; Chénard-Poirier, M; Dolling, D; Clarke, M; Figueiredo, I; Bertan, C; Yuan, W; Ferreira, A; Chistova, R; Boysen, G; Perez, DR; Tunariu, N; Mateo, J; Wotherspoon, A; Chau, I; Cunningham, D; Valeri, N; Carreira, S; de Bono, J (2018-12)

  BACKGROUND: Loss of ataxia telangiectasia mutated (ATM), a key protein regulating DNA repair signaling, has been suggested to increase sensitivity to DNA damaging agents. We conducted a study analyzing the loss of ATM ...
• Androgen receptor-modulatory microRNAs provide insight into therapy resistance and therapeutic targets in advanced prostate cancer. 

  Fletcher, CE; Sulpice, E; Combe, S; Shibakawa, A; Leach, DA; Hamilton, MP; Chrysostomou, SL; Sharp, A; Welti, J; Yuan, W; Dart, DA; Knight, E; Ning, J; Francis, JC; Kounatidou, EE; Gaughan, L; Swain, A; Lupold, SE; de Bono, JS; McGuire, SE; Gidrol, X; Bevan, CL (2019-07)

  Androgen receptor (AR) signalling is a key prostate cancer (PC) driver, even in advanced 'castrate-resistant' disease (CRPC). To systematically identify microRNAs (miRs) modulating AR activity in lethal disease, ...
• Systematic review of methodology used in clinical studies evaluating the benefits of proton beam therapy Clinical and Translational Radiation Oncology 

  Hall, E
• Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer. 

  Woolston, A; Khan, K; Spain, G; Barber, LJ; Griffiths, B; Gonzalez-Exposito, R; Hornsteiner, L; Punta, M; Patil, Y; Newey, A; Mansukhani, S; Davies, MN; Furness, A; Sclafani, F; Peckitt, C; Jiménez, M; Kouvelakis, K; Ranftl, R; Begum, R; Rana, I; Thomas, J; Bryant, A; Quezada, S; Wotherspoon, A; Khan, N; Fotiadis, N; Marafioti, T; Powles, T; Lise, S; Calvo, F; Guettler, S; von Loga, K; Rao, S; Watkins, D; Starling, N; Chau, I; Sadanandam, A; Cunningham, D; Gerlinger, M (2019-07-08)

  Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance landscape in 35 RAS ...

View more